Bao Rui Announces Loan Disclosure Under Regulations

Release Date: 1150703 Announcement Date: 1150702 Announcement Time: 214129 Company Code: 6472 Company Name: Bao Rui Subject: The company and its subsidiaries announce in accordance with Article 22, Paragraph 1, Item 1 of the "Regulations on Loan and Guarantee Handling for Publicly Listed Companies" Applicable Clause: Clause 23 Date of Fact: 1150702 Explanation: 1. Date of Fact: 115/07/02 2. The outstanding loan balance of a publicly listed company and its subsidiaries to others exceeds 20% of the latest financial statements' net assets: (1) Name of the company receiving the loan: Bora Pharmaceutical Holdings, LLC (2) Relationship with the company receiving the loan: It is a 100% indirectly held subsidiary of the company (loaned by the subsidiary Upsher-Smith Laboratories, LLC) (3) Loan limit (thousand yuan): 14,176,296 (4) Outstanding loan balance as of the date of fact (thousand yuan): 798,000 (5) Reason for the loan as of the date of fact: To strengthen the operational funds needed to obtain U.S. drug certifications and related rights (1) Name of the company receiving the loan: Bora Pharmaceuticals USA Inc. (2) Relationship with the company receiving the loan: It is a 100% directly held subsidiary of the company (loaned by the subsidiary Bora Global Ltd.) (3) Loan limit (thousand yuan): 3,939,565 (4) Outstanding loan balance as of the date of fact (thousand yuan): 2,601,480 (5) Reason for the loan as of the date of fact: To strengthen the operational funds needed to acquire CDMO operating assets in Maryland. (1) Name of the company receiving the loan: Bora Pharmaceuticals Inc. (2) Relationship with the company receiving the loan: It is a 100% indirectly held subsidiary of the company (loaned by the subsidiary Bora Pharmaceuticals USA Inc.) (3) Loan limit (thousand yuan): 27,110,314 (4) Outstanding loan balance as of the date of fact (thousand yuan): 798,000 (5) Reason for the loan as of the date of fact: To strengthen the operational funds needed for Bora Pharmaceuticals Inc. to expand its CDMO business. (1) Name of the company receiving the loan: Upsher-Smith Laboratories, LLC (2) Relationship with the company receiving the loan: It is a 100% indirectly held subsidiary of the company (loaned by the subsidiary TWi Pharmaceuticals USA, Inc.) (3) Loan limit (thousand yuan): 2,464,916 (4) Outstanding loan balance as of the date of fact (thousand yuan): 1,188,265 (5) Reason for the loan as of the date of fact: To strengthen operational funds and convert overdue accounts receivable to other receivables. (1) Name of the company receiving the loan: Bora Pharmaceuticals Injectables Inc. (2) Relationship with the company receiving the loan: It is a 100% indirectly held subsidiary of the company (loaned by the subsidiary Bora Pharmaceuticals USA Inc.) (3) Loan limit (thousand yuan): 27,110,314 (4) Outstanding loan balance as of the date of fact (thousand yuan): 239,400 (5) Reason for the loan as of the date of fact: To strengthen operational funds and repay loans. 3. Outstanding loan balance as of the date of fact (thousand yuan): 5,625,145 4. The ratio of the outstanding loan balance to the latest financial statements' net assets of the publicly listed company as of the date of fact: 38.61 5. Source of the company's loans to others: The subsidiaries themselves 6. Other matters to be stated: None.